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SUMMARY
Neuropilin-1 (NRP1) guides the development of the nervous and vascular systems. Binding to either
semaphorins or VEGF, NRP1 acts with plexins to regulate neuronal guidance, or with VEGFR2 to
mediate vascular development. We have generated two monoclonal antibodies that bind to the
Sema- and VEGF-binding domains of NRP1, respectively. Both antibodies reduce angiogenesis
and vascular remodeling, while having little effect on other VEGFR2-mediated events. Importantly,
anti-NRP1 antibodies have an additive effect with anti-VEGF therapy in reducing tumor growth.
Vessels from tumors treated with anti-VEGF show a close association with pericytes, while tumors
treated with both anti-NRP1 and anti-VEGF lack this organization. We propose that blocking NRP1
function inhibits vascular remodeling, rendering vessels more susceptible to anti-VEGF therapy.INTRODUCTION
Many proteins that were originally discovered to be re-
quired for axon guidance during neuronal development
have been more recently shown to play critical roles in
vascular development (Carmeliet and Tessier-Lavigne,
2005). One such family of axon guidance molecules is the
semaphorin ligands and their receptors, the neuropilins
(NRPs) and plexins. NRP1 was first characterized as a
semaphorin receptor mediating axon growth cone col-
lapse (He and Tessier-Lavigne, 1997; Kolodkin et al.,
1997). It was subsequently shown that NRP1 is also an
isoform-specific VEGF receptor expressed on tumor andendothelial cells (ECs; Soker et al., 1998), prompting con-
siderable efforts to understand the role of NRPs in vascu-
lar and tumor biology (Klagsbrun et al., 2002; Bielenberg
et al., 2006).
Genetic studies have provided strong evidence that
Nrp1 is required for vascular morphogenesis. Loss ofNrp1
function results in vascular remodeling and branching de-
fects (Kawasaki et al., 1999), a phenotype that can be fur-
ther enhanced by the loss of Nrp2 function (Takashima
et al., 2002). These results suggest that early in develop-
ment Nrp1 and Nrp2 may have overlapping functions;
however, the expression of each Nrp is partitioned later
in development, with Nrp1 being expressed primarily inSIGNIFICANCE
Bevacizumab is an approved antiangiogenic therapy that has shown promise for reducing tumor growth and
extending survival of patients, particularly when used in combination with chemotherapy. However, some tumors
are less responsive to VEGF blockage, promoting the search for additional therapies to augment the effects of
bevacizumab. This report describes the generation of antibodies targeting NRP1, which was originally discovered
as a receptor for the neuronal chemorepellent semaphorin 3A but was subsequently shown to also bind VEGF.
Interestingly, blocking NRP1 function selectively disrupts remodeling of developing vasculature and combines
with anti-VEGF therapy to further reduce tumor growth. Based on these results, it is proposed that NRP1 anti-
bodies may render tumor vessels more responsive to anti-VEGF therapy.Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 53
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Anti-NRP1 Antibodies Augment Anti-VEGF Therapyarteries, and Nrp2 in veins and lymphatic vessels (Herzog
et al., 2001; Yuan et al., 2002). Notably, loss of Nrp2 func-
tion alone specifically impairs lymphatic development.
As Nrp1 is expressed in many other cell types during
development, the role of vascular Nrp1 was addressed
through the generation of an EC-specific knockout (Gu
et al., 2003), which resulted in vascular defects similar to
those seen in the null allele. Interestingly, this study also
showed that Sema3A binding to NRP1 is not required for
vascular development. In another study, defects were ob-
served in the guidance of endothelial tip cells in the devel-
oping hindbrain in Nrp1 KO embryos (Gerhardt et al.,
2004).
Two broad hypotheses exist for how NRP1 acts to reg-
ulate EC function. First, it has been proposed that NRP1
enhances VEGF binding to VEGFR2, thus enhancing
VEGFR2 signaling. This idea is supported by experiments
in which VEGF effects were examined on ECs overex-
pressing VEGFR2, in the presence or absence of NRP1
expression. These comparisons show enhanced migra-
tion, VEGFR2 activation, and VEGF binding to cells ex-
pressing both receptors (Soker et al., 2002). However,
data have been published that support the alternative
possibility thatNRP1may signal independently of VEGFR2
to regulate EC migration and/or adhesion (Wang et al.,
2003; Murga et al., 2005).
To begin to distinguish these hypotheses, we generated
two high-affinity monoclonal antibodies that bind different
domains of NRP1 and compared them in neuronal and EC
assays. Our results provide evidence that NRP1 plays a
key role in modulating ECmotility, and that its function ex-
tends beyond its previously assigned role as an enhancer
of VEGFR2 signaling. In addition, we show that blocking
NRP1 function can enhance the ability of anti-VEGF to
block tumor growth, thus identifying NRP1 as a target
for antitumor therapy in combination with anti-VEGF.
RESULTS
Generation of Phage-Derived Monoclonal
Anti-NRP1 Antibodies
To distinguish between NRP1-mediated responses to
semaphorin and VEGF on endothelial cells (ECs), we gen-
erated two high-affinity phage-derived monoclonal anti-
bodies (mAbs) designed to block the function of each
NRP1 ligand. OnemAb was targeted to the primary region
for Sema3A binding, the CUB (or a1–a2) domains, termed
anti-NRP1A; and another mAbwas targeted to the primary
region for VEGF binding, the coagulation V/VIII factor
(or b1–b2) domains, termed anti-NRP1B (Figure 1A). A de-
tailed description of the generation and screening for anti-
NRP1 mAbs will be discussed elsewhere (Liang et al.,
2007). Both anti-NRP1 mAbs bind with similar affinities
to human and murine NRP1 (Figure 1B; human NRP1
shown) but do not bind to NRP2 (data not shown). Anti-
NRP1A binds to murine and human NRP1 with a Kd of
7.8 nM and 0.9 nM, respectively, whereas anti-NRP1B
binds to murine and human NRP1 with a Kd of 1.3 nM
and 0.4 nM, respectively.54 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.Selective Actions of Anti-NRP1A and Anti-NRP1B
on Sema3A Function and VEGF Binding
We tested the ability of each anti-NRP1 mAb to block
binding of VEGF165 to NRP1 in both an ELISA format
and cell-based binding. Anti-NRP1B strongly blocked
VEGF binding to NRP1 and ECs, whereas anti-NRP1A
did not (Figures 1C and 1D). These results fit with the ob-
servation that the a1–a2 domains of NRP1 are not neces-
sary for VEGF binding (Gu et al., 2002).
We next examined the effect of the antibodies on
Sema3A function. It has been previously suggested that
Sema3A and VEGF165 may share overlapping binding
domains in the N-terminal region of the b1 domain, and
thus may compete for binding to NRP1 (Gu et al., 2002;
Miao et al., 1999). Therefore, it seemed possible that a
single anti-NRP1 mAb would block both Sema3A and
VEGFbinding.We tested the ability of our anti-NRP1mAbs
to block Sema3A-induced axon growth cone collapse.
Dorsal root ganglia (DRG) were dissected from mouse
E12.5 embryos and cultured to establish sensory neuron
growth cones that were responsive to Sema3A/NRP1-
dependent collapse (He and Tessier-Lavigne, 1997). Add-
ing Sema3A to these cultures caused growth cones to
retract their actin-rich structures (Figure S1A, arrowheads,
in the Supplemental Data available with this article online).
However, if anti-NRP1A was added at the same time as
Sema3A, collapse was completely blocked (Figure S1B).
In contrast, anti-NRP1B had no effect on Sema3A-induced
collapse.
These two mAbs thus have functionally distinct actions:
anti-NRP1A blocks Sema3A function but does not inter-
fere with VEGF binding to NRP1, whereas anti-NRP1B
blocks VEGF binding to NRP1 without effect on Sema3A
function. Further studies showed that neither mAb blocks
Sema3F/NRP2-dependent collapse of E17 hippocampal
growth cones (Figure S1B), consistent with the observa-
tion that neither mAb binds NRP2. These mAbs thus pro-
vide selective tools to dissect the role of NRP1 in vascular
biology.
Both Anti-NRP1A and Anti-NRP1B Reduce
VEGF165-Dependent Endothelial Cell
Migration and Bead Outgrowth
We next investigated the role of NRP1 in VEGF-driven EC
migration. Using a transwell system, human umbilical vein
endothelial cells (HUVECs) were introduced into the top
chamber, while VEGF was added to the bottom chamber
to promote EC migration. ECs that had migrated to the
bottom chamber were then quantified (Figure 2A). An
anti-VEGF mAb was used as a positive control to block
VEGF-driven EC migration (the cross-species reactive
anti-VEGF mAb B20.4.1 was used in all experiments
unless stated otherwise; Liang et al., 2006).
To determine whether NRP1 function is required for EC
migration, anti-NRP1 mAbs were added to cells in the top
chamber just prior to the addition of VEGF. Interestingly,
both anti-NRP1A and anti-NRP1B significantly reduced
EC migration, with anti-NRP1B providing a stronger block
of migration (Figure 2A). Similar results were obtained
Cancer Cell
Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 1. Characterization of Anti-NRP1A and Anti-NRP1B
Antibodies
(A) Schematic representation of Sema- and VEGF-binding regions on
NRP1 relative to anti-NRP1A and anti-NRP1B epitope regions.
(B) ELISA assay detecting binding of anti-NRP1A and anti-NRP1B to
hNRP1.
(C) Blocking of VEGF binding to NRP1 by anti-NRP1 antibodies. In-
creasingamountsof anti-NRP1Aor anti-NRP1Bwerepreincubatedwith
plates coated with human NRP1.Fc (5 mg/ml; NRP1 including a1,a1,
b1,b2,c fused to human Fc) for 1–2 hr, followed by the addition of
pretitrated biotinylated human VEGF165 (1 nM) for 15min. The percent-
age of bound VEGF165 was detected by streptavidin-HRP conjugates.using two other types of EC lines, HUAECs and HAECs
(data not shown).
To further dissect the role of NRP1 in more complex EC
functions, we employed an in vitro system of angiogenic
sprouting (Nakatsu et al., 2003). ECs coated on beads
sprout over a 7 day period, resulting in multiple well-
defined vessel structures protruding from each bead
(Figure 2B; control). Adding either anti-NRP1 mAbs to
these cultures resulted in a reduction in vessel length,
with anti-NRP1B also showing a decrease in the number
of sprouts (Figures 2B and 2C). Anti-VEGF was used as
a positive control and completely blocked sprouting in
this assay.
The finding that anti-NRP1B interferes with VEGF ac-
tions was perhaps not surprising, since it blocks VEGF
binding to NRP1, but the finding that anti-NRP1A also
affects VEGF function was unexpected, since it does not
interfere with VEGF binding to NRP1. There are several
possible explanations for why an antibody targeting the
semaphorin-binding region of NRP1 would affect EC
behavior. First, it seemed possible that anti-NRP1A pro-
motes NRP1 internalization. To address this possibility,
we preincubated ECs with anti-NRP1A at 37C for either
5 min, 2 hr, or 20 hr, and then performed FACS analysis
with anti-NRP1B to determine the level of NRP1 on the
cell surface (Figure S2A). No difference was observed
between treatments, suggesting that anti-NRP1A did not
cause significant internalization of NRP1. Similar results
were seen with anti-NRP1B (Figure S2B).
A second possible explanation for why the anti-NRP1
mAbs reduce EC migration is that they might reduce EC
adhesion to the extracellular matrix and/or reduce ECmo-
tility in general. It has been reported that NRP1 is required
for cell attachment (Murga et al., 2005), and migration
defects could be secondary to such an affect. Therefore,
we examined the effects of the anti-NRP1 mAbs on EC
adhesion to fibronectin, an extracellular matrix substrate;
no defects were observed as compared to control mAbs
(Figure S2C). To determine whether the anti-NRP1 mAbs
disrupt EC motility generally, we examined whether they
reduce migration of ECs in response to other growth fac-
tors but found that they did not blockmigration induced by
either bFGF or HGF (Figure S2D; HGF data not shown).
Lastly, it has been reported that Sema3A regulates EC
migration and adhesion (Miao et al., 1999), and that
Sema3A may act in an autocrine manner to modulate EC
adhesion through inhibiting integrin function (Serini et al.,
2003). We tested this possibility by employing the same
Sema3A used in the neuronal growth cone collapse
assays shown in Figure S1, in EC assays. We observed no
block of EC adhesion or migration in the presence of dif-
ferent concentrations of Sema3A (Figure S3) and therefore
could not further examine the possibility that anti-NRP1A
acts by inhibiting Sema3A function on ECs.
(D) Blocking of I125-VEGF165 binding to HUVECs. Cells were incubated
with control and anti-NRP1 antibodies at the indicated concentrations
for 30 min followed by incubation with 0.1 nM I125-VEGF165 for 2 hr
at 4C. n = 3 for each condition.Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 55
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Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 2. Anti-NRP1 mAbs Reduce VEGF-Induced Migration, In Vitro Sprouting, and In Vivo Neovascularization
(A) HUVECs with indicated mAbs (10 mg/ml) were allowed to migrate in the presence or absence of 10 ng/ml VEGF overnight. Quantification of
migration assay (n = 6 for each condition). *p = 0.00003, **p = 0.1 3 1010.
(B) Endothelial bead sprouting assay with concentric rings drawn at 100, 200, and 300 mm from the center of the bead.
(C) Quantification of bead sprouting assay; n = 12–14 beads per condition. Sprouts weremarked if they passed each respective line, giving an average
number of sprouts at each given length.
(D) Representative corneal images illustrating the effects of intraconjunctival injection of indicated antibody (10 mg/kg) on VEGF-induced angio-
genesis. VEGF (150 ng) and antibody are both added to the pellet (P). Arrows point to area of neovascularization outlined in red.
(E) Quantification of the pixel counts from the circled areas in (D). Averages of the results from each condition were shown (n = 5–7). *p = 0.000004,
**p = 0.7 3 109.Both Anti-NRP1 Antibodies Reduce
Neovascularization in the Rat Corneal Pocket Assay
Having observed a strong reduction in EC migration and
vessel sprouting by blocking NRP1 in the in vitro assays,56 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.we next examined whether NRP1 is required for in vivo an-
giogenesis. This was accomplished using the rat corneal
pocket assay, in which pellets containing VEGF were ad-
ded to the avascular cornea to induce neovascularization.
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dextran and then imaged. Anti-VEGF resulted in a com-
plete block of neovascularization, and both anti-NRP1A
andanti-NRP1Bsignificantly reduced vessel ingrowth (Fig-
ures 2D and 2E).
NRP1 Is Necessary for Vascular Remodeling
in the Mouse Retina
Phenotypes observed in the Nrp1 knockout mice are con-
sistent with a defect in vascular remodeling (Gu et al.,
2003; Kawasaki et al., 1999; Takashima et al., 2002). We
next tested the requirement of NRP1 for vascular remod-
eling by analyzing the effects of systemic treatment with
the anti-NRP1 mAbs on the developing mouse retina,
which allowed us to investigate the stereotyped events
of vascular sprouting, remodeling, and maturation (Dorrell
and Friedlander, 2006). At birth, an astrocytic network is
in place to guide ECs sprouting from central retinal artery
located near the optic nerve head (ONH). After one day of
postnatal life (P1) the retinal vasculature has developed
a morphogenic furrow in the nerve fiber layer (NFL), lying
superficial to the ganglion cell layer, that begins to extend
toward the edge of the retina in a concentric pattern,
reaching halfway by P5 (Figure 3A). Over the next 3 days,
the furrow continues to extend to the edge of the retina,
while the vascular plexus closest to the ONH undergoes
stereotyped remodeling, consisting of thinning of the
vascular plexus into a refined capillary network in the
NFL (Figure 3B), and sprouting of vessels into deeper
layers of the retina (Figure 3F).
Antibodies were injected into neonatal mice beginning
at P1, followed by injections every other day until retinas
were collected at P5 and P8. To visualize the vasculature,
retinas were stained with isolectin B4 (green; Figure 3C).
While the refined capillary network of the IgG control
group is well established between P5 and P8, this vascular
remodeling is inhibited by both anti-NRP1 mAbs. We
quantified this difference by comparing the vascular den-
sity from representative images taken of the NFL vascular
network in regions adjacent to the ONH (Figure 3D).
Because treatment with either anti-NRP1 mAb results
in a strong inhibition of vascular remodeling, vascular
density is significantly higher in both anti-NRP1A- and
anti-NRP1B-treated retinas as compared to controls. In-
terestingly, the developmental furrow continues to extend
in both anti-NRP1 mAb-treated retinas, with only a slight
inhibition of extension in the anti-NRP1B-treated animals
(Figure 3E). This suggests that development of the retina
is not generally inhibited, but that there is a specific
block in vascular remodeling when treating with either
anti-NRP1 mAb.
In contrast to anti-NRP1mAbs, anti-VEGF treatment re-
sulted in a reduction of retinal vascular density (Figures 3C
and 3D). At a qualitative level, vessels in anti-VEGF-
treated retinas have a reduced complexity at P8, a trend
that is present at P5. These data suggest that anti-VEGF
treatment results in block of initial sprouting and/or vas-
cular regression. Interestingly, systemic delivery of anti-
VEGF does not significantly reduce the extension of thevascular furrow (Figure 3E). This may be a result of poor
mAb diffusion to the extending tip cells (Gerhardt et al.,
2003).
Evaluating P8 retinas also allowed us to further investi-
gate the effects of mAb treatment on angiogenic sprout-
ing. Between P5 and P8, vessels begin to sprout from the
NFL vascular network into deeper vascular layers resulting
in the formation of the outer plexiform layer (OPL) vascular
network, which is superficial to the outer nuclear layer and
is the deepest vascular bed in the retina (Figure 3F). Later
in development, sprouting from collaterals that gave rise
to the OPL results in an intermediate vascular bed, termed
the inner plexiform layer (IPL). Images taken from the OPL
at P8 show an inhibition of sprouting by both anti-NRP1
mAbs, and anti-VEGF (Figure 3G). In the case of the anti-
NRP1 mAbs, it remains to be determined whether inhibi-
tion of OPL vascular sprouting is an indirect consequence
of blocking vascular remodeling of the NFL vascular
plexus.
The different phenotypes observed in retinas taken
from animals systemically treated with either anti-NRP1A
or anti-NRP1B, as compared to anti-VEGF, suggest that
NRP1may regulate EC function bymechanismsother than
enhancing VEGFR2 signaling.
Blocking NRP1 Function Has Little Effect
on VEGFR2 Signaling
We next investigated the requirement of NRP1 in EC pro-
liferation and vascular permeability—two defining cellular
activities induced by VEGF. Remarkably, treatment with
either anti-NRP1 mAb had no effect on VEGF-induced
permeability, whereas anti-VEGF provided a strong block
(Figures 4A and 4B). A similar trend was observed when
testing for VEGF-induced EC proliferation, with anti-
NRP1A showing no block of proliferation, and anti-NRP1B
only a slight dose-responsive reduction (Figure 4C). These
results support published data showing that siRNA knock-
down of NRP1 in ECs results in only a partial inhibition
of VEGF-induced proliferation (Murga et al., 2005) and
suggests that NRP1’s primary role in VEGF-driven EC
behaviors is to mediate cell migration. Notably, the same
nonsaturating concentration range of VEGF (10–20 ng/ml;
Figure S4) was used in all in vitro cellular and signaling
experiments.
We next studied the effect of anti-NRP1 mAbs on
VEGFR2 signaling. VEGF binds to the second and third
extracellular IgG domains of VEGFR2 and activates the re-
ceptor by autophosphorylation (Dougher and Terman,
1999; Takahashi et al., 2001). In contrast to anti-VEGF,
which completely blocked VEGFR2 phosphorylation
induced by VEGF, anti-NRP1A did not significantly change
VEGFR2 phosphorylation levels, whereas anti-NRP1B
resulted in only a modest reduction (Figure 4D).
Rather than regulating VEGFR2 phosphorylation level
directly,NRP1mayact tomodulate specificVEGFR2path-
ways. To address this possibility, we studied the effect of
anti-NRP1 mAbs on downstream signaling events medi-
ated by VEGFR2. VEGFR2 has been shown to induce EC
proliferation through activation of the mitogen-activatedCancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 57
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Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 3. Anti-NRP1 mAbs Inhibit Vascular Remodeling in the Developing Retina
(A) Schematic of vascular development in the mouse retina from postnatal day 5 (P5) to P8. Vessels extend in a concentric patter to the retina edge.
The optic nerve head (ONH) is located in the center of the retina.
(B) Vascular remodeling near the ONH takes place between P5 and P8. Images in (C) were acquired from areas boxed in schematic.
(C) Confocal images from the vascular RGC layer in control IgG-, anti-VEGF-, anti-NRP1A-, and anti-NRP1B-treated animals.
(D) Quantification of vascular density; total pixel count from 12 representative images from four treated retinas of each condition. *p = 0.006,
**p < 0.0001.
(E) Quantification of vascular extension. Measured by the ratio of the distance from the ONH to the edge of the vasculature, over the distance from the
ONH to the edge of retinal cup. Twelve representative measurements were taken from four treated retinas.
(F) Schematic of vascular sprouting into deeper layers of the retina. Vessels extend sprouts to the outer plexiform layer (OPL) and form a plexus. Later
spouts arise between the NFL and OPL layers, eventually giving rise to the inner plexiform layer (IPL).
(G) Confocal images from the vascular OPL layer. Vasculature stained with isolectin B4. Scale bar, 50 mm (C and G).protein kinases Erk1/2 (Rousseau et al., 1997; Takahashi
et al., 1999), and to regulate EC survival and vascular per-
meability through the PI3-kinase/Akt pathway (Chen et al.,58 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.2005; Gerber et al., 1998; Six et al., 2002). Consistent
with the observation that anti-NRP1 mAbs did not signifi-
cantly change VEGF-induced EC proliferation or vascular
Cancer Cell
Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 4. Effects of Anti-NRP1mAbs on VEGF-Induced Vascular Permeability, HUVECProliferation, VEGFR2 Phosphorylation, and
VEGFR2 Downstream Signaling
(A) Mouse skin vascular permeability assay. Images in the same row were taken from the skin of the same animal. Blue stain represents Evan’s blue
leakage from the vasculature.
(B) Quantification of the Evan’s blue dye extracted from skin samples in the permeability assay. Values shown are the average of six independent
experiments. Neither anti-NRP1A- nor anti-NRP1B-treated skin samples were significantly different from control (p = 0.69 for anti-NRP1A, and
p = 0.989 for anti-NRP1B).
(C) Quantification of HUVEC proliferation in the presence or absence of 10 ng/ml VEGF as determined by BrdU incorporation (n = 5, each condition).
(D) VEGFR2 phosphorylation level in HUVECs detected by ELISA assay using antibodies that recognized total or tyrosine-phosphorylated VEGFR2.
VEGF was added at 20 ng/ml for 10 min to induce the phosphorylation of VEGFR2; n = 3 for each condition. VEGFR2 phosphorylation level in anti-
NRP1A (10 mg/ml)-treated cells was not significantly different from that in the control group (p = 0.1). *p = 0.0002.
(E) Immunoblot analysis of HUVEC lysates. Cells were treated with the indicated antibodies at 50 mg/ml for 30 min, followed by a 10 min incubation
with 20 ng/ml VEGF.
(F) Immunoprecipitation with anti-VEGFR2. Cells were treated with the indicated antibodies at 25 mg/ml for 30 min and then incubated with 20 ng/ml
VEGF for 30 min on ice and then for 8 min at 37C.Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 59
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not affect VEGF-induced phosphorylation of Erk1/2 or
Akt. On the other hand, inhibiting NRP1 function with
anti-NRP1 mAbs significantly reduced EC migration
(Figure 2A). It is possible that NRP1 specifically regulates
VEGFR2 pathways required for cell motility, such as the
p38 MAP kinase pathway, which has been shown to be
required for VEGF-driven actin reorganization and cell
migration in ECs (Rousseau et al., 1997). Anti-NRP1A and
anti-NRP1B treatments both resulted in a slight reduction
in p38 phosphorylation level in HUVECs (Figure 4E). How-
ever, the mild decrease in p38 phosphorylation alone is
unlikely to account for the strong reduction we observed
in the migration and sprouting assays (Figure 2) or explain
the qualitatively different phenotypes observed between
the anti-NRP1mAbs and anti-VEGFmAb treatments in the
retinal vascular remodeling experiments (Figure 3).
Lastly,we tested theeffect of anti-NRP1mAbsonVEGF/
NRP1/VEGFR2complex formation. As reportedpreviously
(Soker et al., 2002), in the presence of VEGF, NRP1 can
be coimmunoprecipitated from HUVEC lysate with anti-
VEGFR2 antibodies (Figure 4F, lane 2). This interaction
was reduced by anti-VEGF (Figure 4F, lane 3). Interest-
ingly, both anti-NRP1A and anti-NRP1B strongly inhibit the
formation of theNRP1/VEGFR2 complex (Figure 4F, lane 4
and 5). This observation is surprising, as anti-NRP1A did
not alter VEGF binding to NRP1 or ECs (Figures 1C and
1D), and had little effect on VEGFR2 activation or down-
stream signaling. These results suggest that anti-NRP1A
and anti-NRP1B may be acting via the same mechanism
to inhibit VEGF-drivenmotility events (i.e., bydisrupting the
NRP1/VEGFR2 complex).
Anti-NRP1 in Combination with Anti-VEGF Shows
an Additive Effect in Reducing Tumor Growth
Blocking the VEGF pathway has been proven to reduce
neovascularization in mouse tumor models and in human
cancers (Ferrara and Kerbel, 2005). However, it is believed
that some tumors are less dependent on VEGF for vessel
formation or may become insensitive to anti-VEGF thera-
pies (Jain et al., 2006; Kerbel et al., 2001). To determine if
NRP1 blockade could enhance the tumor growth inhibi-
tion (TGI) provided by blocking VEGF, we selected several
xenograft models known to exhibit varying sensitivity to
anti-VEGF therapy. Since mouse stromal VEGF, in addi-
tion to tumor-derived VEGF, has been shown to impact
tumor growth, we used anti-VEGF mAbs that recognize
both murine and human VEGF (Liang et al., 2006).
These experiments were designed to test the effect of
blocking NRP1 alone (anti-NRP1A in red, anti-NRP1B in
green, Figure 5), and in combination with anti-VEGF (anti-
NRP1A combination in purple, anti-NRP1B combination in
light blue, Figure 5). Also included were single-agent anti-
VEGF (blue, Figure 5) and isotype control mAbs (black,
Figure 5). SK-MES-1 is a NSCLC xenograft model that
expresses NRP1 primarily in vascular and stromal tissue,
with an intermediate level of expression in tumor cells
(Figure 5A and Figure S5A; IHC control shown in
Figure S5B). In this model, anti-VEGF provided a 52%60 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.TGI, single-agent anti-NRP1B caused a 37% TGI, and
anti-NRP1A had no significant effect on TGI (see Experi-
mental Procedures for calculation; Figure 5B).
Most striking was the additive effect seen with either
anti-NRP1 mAb in combination with anti-VEGF. In com-
bination with anti-VEGF, anti-NRP1A increased the TGI
to 70%, and anti-NRP1B increased the TGI to 77% (Fig-
ure 5B). Similar results were obtained in the H1299NSCLC
xenograft model, which also expresses NRP1 in vascular
and stromal tissue at high levels, but in tumor cells to a
lesser extent (Figure 5A and Figure S5A). Single-agent
anti-NRP1B showed 39% TGI, anti-VEGF showed 28%
TGI, andboth in combination showed51%TGI (Figure 5C).
Animals in the SK-MES-1 model were dosed to day 35
and followed to day 60 to examine the delay in tumor
growth (animals were removed from the study when tumor
sizes exceeded 1500 mm3; no animals were removed as
a result of toxicity). The Kaplan-Meier plot shows a signif-
icant effect of both anti-NRP1 mAb combination arms in
delaying tumor growth as compared to single-agent arms
(Figure 5D). Measurements of tumor growth delay (TGD;
see Experimental Procedures for calculations) show no
single-agent delay for anti-NRP1A, a 24% TGD for anti-
NRP1B, 60% for anti-VEGF, 93% for anti-NRP1A combi-
nation arm, and 96% for anti-NRP1B combination arm.
Blocking NRP1 Function Alters Tumor Vascular
Morphology and Further Reduces Vascular Density
in Combination with Anti-VEGF
To determine if blocking NRP1 may alter tumor cell func-
tion directly, we assayed the effects of anti-NRP1 mAbs
on SK-MES-1 tumor cell proliferation and antibody-
dependent cell-mediated cytotoxicity (ADCC; Figure S6).
FACS analysis of the SK-MES-1 cell line confirms that
NRP1 is the predominant VEGF receptor, and VEGFR3
is moderately expressed, while VEGFR1, VEGFR2, and
NRP2 showed little expression (Figure S6A). VEGF had
no effect on SK-MES-1 tumor cell proliferation. Likewise,
anti-NRP1 mAb alone or in combination with anti-VEGF
did not alter proliferation of SK-MES-1 tumor cells in vitro
(Figure S6B). Next, we tested if anti-NRP1 mAbs may
induce ADCC in an in vitro cellular model. Using anti-
HER2 as a positive control in BT-474 tumor cells, we ob-
served that anti-NRP1 mAbs did not induce cytotoxicity
in either the BT-474 or SK-MES-1 cell lines (Figure S6C).
These results suggest that anti-NRP1 mAbs inhibit
SK-MES-1 tumor growth mainly by altering vessels.
To further evaluate the vascular changes in SK-MES-1
tumors, an additional study was performed, and tumors
were harvested within the same time window for histolog-
ical analysis (Figure 6A). Interestingly, both anti-NRP1B
and anti-VEGF significantly reduced vascular density,
while combination treatment resulted in further reduction
of vascular density (Figure 6B; vessels were analyzed from
the peripheral ridge of viable tissue). Although we did not
see an effect on SK-MES-1 tumor cell proliferation in vitro
(Figure S6B), the further reduction of vascular density
caused by the combination treatment resulted in a reduc-
tion of tumor cell proliferation in vivo (Figure S7).
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Models Showing Single-Agent and Addi-
tive Effect of Anti-NRP1 mAbs in Combi-
nation with Anti-VEGF
(A) Immunohistochemistry of NRP1 (red) in
SK-MES-1 and H1299 control tumor sections.
PECAM is shown in green. Scale bar, 100 mm.
(B and C) Mean tumor volume graph of the
SK-MES-1 (B) and H1299 (C) tumor models.
Animals were dosed twice weekly i.p. with
10 mg/kg anti-NRP1 and/or 5 mg/kg of anti-
VEGF or control antibody for 5 weeks.
(D) Kaplan-Meier plot for the SK-MES-1 tumor
model.We next investigated differences in vascular morphol-
ogy among the various treatment groups (Figure 6C). Con-
trol IgG-treated tumors had large unorganized vessels,
which were surrounded by pericytes, but lacked the wrap-
ping morphology often seen when staining with anti-
aSMA. Vessels in anti-VEGF-treated tumors showed not
only a significant decrease in vascular density, but also a
very close association with pericytes. Importantly, vessels
in tumors treated with anti-NRP1B and anti-VEGF in com-
bination lacked close pericyte associations, while show-
ing a stronger vascular density reduction than those
tumors treated with anti-VEGF alone. These observations
were confirmed by quantification of pericyte/vessel ratios
(Figure 6D).
Although control and anti-VEGF tumors shared similar
pericyte-to-vessel ratios in the SK-MES-1 model, anti-
VEGF-treated tumor vessels were qualitatively different
from the other treatment groups. The majority of vessels
in the anti-VEGF-treated tumors showed a tight pericyte
wrapping morphology (Figure 6E; arrows), a phenotype
that was rarely observed in the other treatment groups.
Similar results were also obtained in the Fo5, allograft
murine breast tumor model (Figure S8). However in this
model, tumors treated with control IgG (Figure S8C), aswell as anti-NRP1 and combination treatments (Fig-
ures S8E and S8F), lacked pericyte coverage altogether,
whereas anti-VEGF-treated tumors showed a massive
increase in pericyte coverage (Figure S8D, quantified
in Figure S8I). Additionally, Fo5 tumors analyzed by
H&E staining appeared to show an increase in necrosis
upon anti-NRP1 and anti-VEGF combination treatment
(Figure S9).
Blocking NRP1 Function in Combination
with Anti-VEGF in the Developing Retina
Enhances Vascular Regression
Having observed that combining anti-NRP1 with anti-
VEGF in tumors results in tumor vessels that lack features
of maturation, including pericyte investment (Figure 6),
and in light of results showing that NRP1 is required for
vascular remodeling in the developing retina (Figure 3),
we propose a model in which blocking NRP1 function in
newly formed vessels inhibits vessels from undergoing
remodeling and subsequent maturation, rendering ves-
sels dependent on VEGF for survival (Figure 7A). A
prediction of this model would be that combining anti-
NRP1 with anti-VEGF in the developing retina would result
in a stronger reduction in vascular density compared toCancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 61
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Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 6. Anti-NRP1B in Combination with Anti-VEGF Reduces Vascular Density and Pericyte Association with Vessels in Tumors
(A) Mean tumor volume graph of the SK-MES-1 tumor model. Model was repeated to harvest animals at the same time (dashed line, harvested after
day 14) to compare vascular density and architecture. Animals were dosed as described in Figure 5.
(B) Quantification of vascular density. All three treatments reduce vascular density as compared to control: anti-VEGF, **p = 0.001; anti-NRP1B,
*p = 0.01; and combination of anti-NRP1B + anti-VEGF, **p < 0.001. Difference between anti-VEGF and anti-NRP1B + anti-VEGF is p = 0.03, whereas
the anti-NRP1B compared to anti-VEGF is not statistically significant (n = 6–10 images from 2–3 representative tumors; mean pixel number calculated
using Image J).
(C) Confocal images of representative vessels (green; PECAM, ICAM, MECA32 combination stain) and pericyte (red; anti-aSMA) in treated tumors
compared to control.
(D) Quantification of pericyte/vessel ratio. Anti-NRP1B and anti-NRP1B + anti-VEGF combination shows less pericyte coverage as compared to
anti-VEGF treatment alone (*p = 0.02 and *p = 0.05, respectively).
(E) Confocal image of pericyte coverage in anti-VEGF-treated tumors. Arrows point to tight wrapping of pericytes in anti-VEGF-treated tumors. Scale
bar, 50 mm (C and E).62 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.
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Anti-NRP1 Antibodies Augment Anti-VEGF TherapyFigure 7. Potential Model for Additive Effects Seen with Anti-NRP1 and Anti-VEGF
(A) Using developing vessels as a model, we show that NRP1 is required for vascular remodeling. The transition from immature to mature vessels
results in decreased VEGF dependency for vessel survival. In tumors, addition of anti-VEGF forces vessels into a VEGF-independent state, similar
to what is seen naturally during vessel development. We hypothesize that blocking NRP1 in tumors will keep vessels from maturing, thus making
tumor vessels more dependent on VEGF for survival. Therefore, combining anti-NRP1 with anti-VEGF results in further reduction in tumor vessels
and subsequent inhibition of tumor growth.
(B) Confocal images showing combination treatment in neonate mice with anti-NRP1B and anti-VEGF results in further vascular regression in the
developing retina. Images are shown at P8; treatment is as described for Figure 3 (exception: anti-VEGF and anti-NRP1B are dosed half of single agent
alone [5 mg/kg versus 10 mg/kg single agent]). Scale bar, 50 mm.
(C) Quantification of vascular density. Compared to control, anti-VEGF reduces vascular density (*p = 0.0004), anti-NRP1B increases vascular density
(**p < 0.0001), and combination of anti-NRP1B + anti-VEGF further decreases vascular density (**p < 0.0001). Difference between anti-VEGF and
anti-NRP1B + anti-VEGF combination is also highly significant (**p < 0.0001).anti-VEGF treatment alone, as was shown in the
SK-MES-1 tumor model (Figure 6B). To test this possibil-
ity, we treated neonate mice with both anti-NRP1B and
anti-VEGF in combination. Strikingly, the anti-NRP1B +
anti-VEGF combination treatment resulted in a massive
decrease in vascular density (Figure 7B, quantified in
Figure 7C; p < 0.001 when comparing anti-NRP1B +
anti-VEGF to anti-VEGF alone; 100,000–150,000 mean
pixel density is contributed by major vessels that are not
effected by treatment). These data combined with the
additive effect seen in the tumor models suggest that
anti-NRP1 mAb treatments augment anti-VEGF therapy
by further regressing vessels.
DISCUSSION
NRP1 May Act Independently or in Parallel
with VEGFR2 to Mediate EC Migration
We found scant evidence that either anti-NRP1 mAb
affects VEGFR2 phosphorylation and downstream signal-ing. Using the same concentration of VEGF used in the
migration and bead outgrowth assays, we observed only
amild reduction in EC proliferation, VEGFR2 phosphoryla-
tion, and p38-MAPK phosphorylation with anti-NRP1B,
and no reduction with anti-NRP1A (Figure 4; see Figure S4
for VEGF dose response).
Results obtained using the anti-NRP1B mAb, which
blocks VEGF binding to NRP1, supports a mechanism
where one of NRP1’s roles is to enhance VEGFR2 signal-
ing, but only to a modest extent, a conclusion supported
by a recent report showing that a peptide designed to
block VEGFA165 binding to NRP1 reduces VEGF cross-
linking to VEGFR2 and decreases VEGFR2 activation
(Jia et al., 2006). One explanation for the modest effects
of anti-NRP1B on EC proliferation and vascular permeabil-
ity is that different VEGF-induced physiological events
might require differential levels of VEGFR2 activation.
Thus, the slight decrease in VEGFR2 phosphorylation
may be sufficient to inhibit ECmigration, while having little
effect on permeability and proliferation.Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 63
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anti-NRP1 mAbs only has a slight effect on canonical
VEGFR2 signaling (Cross et al., 2003), we investigated
other mechanisms by which blocking NRP1 function may
effect VEGF-driven motility. In particular, we were sur-
prised by the result that an antibody targeting the Sema-
binding region of NRP1, which does not affect VEGF bind-
ing to NRP1, could reduce VEGF-driven motility events
(Figure 2). This did not appear to result from internalization
of NRP1, from a decrease in adhesion, or from a general
decrease in motility of ECs (Figure S2). Likewise, we
were unable to observe any effects of Sema3A on EC
migration or adhesion, contrary to previous reports
(Figure S3; Miao et al., 1999; Serini et al., 2003). Therefore,
it is unlikely that the reduction in VEGF-induced motility
using anti-NRP1A can be explained by disrupting the pro-
posed Sema3A autocrine loop, in which EC-expressed
Sema3A regulates adhesion by modulating integrin func-
tion (Serini et al., 2003).
Lastly, we asked if blocking NRP1 function disrupts
the VEGF/NRP1/VEGFR2 complex. As expected, block-
ing VEGF binding to NRP1 using anti-NRP1B completely
blocks the formation of this complex (Figure 4). Surpris-
ingly, anti-NRP1A also strongly inhibits the formation of
this complex. In light of the fact that anti-NRP1A does
not effect VEGF binding to NRP1 or VEGFR2 signaling,
these data suggest that disrupting NRP1 association
with activated VEGFR2 selectively disrupts EC migration,
further supporting a model in which NRP1 brings unique
machinery to the VEGFR2 complex, acting in parallel
with or independently of VEGFR2 to regulate EC motility.
One molecular candidate regulating this process is NIP
(GIPC), a PDZ domain-containing protein that interacts
directly with NRP1 and potentially plays a role in vesicular
trafficking (Cai and Reed, 1999; De Vries et al., 1998).
Recent findings show that knocking down GIPC results
in similar vascular defects as NRP1 knockdown in zebra-
fish (Wang et al., 2006).
Blocking NRP1 in Tumors Can Augment
Anti-VEGF Effects
Our findings that anti-NRP1 mAbs and anti-VEGF may be
acting by blocking different EC functions and/or signaling
pathways raised the possibility that combining these anti-
bodies in tumor models could have an additive effect in
reducing tumor growth. Indeed, we observed a profound
additive effect when combining anti-NRP1 with anti-
VEGF (Figures 5 and 6). In the case of anti-NRP1A, the
results suggest a synergistic rather than additive effect,
since in multiple tumor models the mean tumor volume
following single-agent anti-NRP1A treatment was not dif-
ferent from control; however, anti-NRP1A in combination
with anti-VEGF significantly enhanced tumor growth inhi-
bition when compared with anti-VEGF alone.
In the case of anti-NRP1B, single-agent treatment re-
sulted in a significant reduction in tumor growth (Figures
5 and 6). Interestingly, these effects are only slightly less
potent than anti-VEGF alone. However, the reduction in
tumor growth from the combination arms for anti-NRP1B64 Cancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc.were profound. We speculate that the single-agent effect
of anti-NRP1B is due to its relatively stronger inhibitory
activity in reducing sprouting and in vivo angiogenesis,
compared to anti-NRP1A. On the other hand, we observed
that both mAbs were equally potent in blocking vascular
remodeling in the mouse retinal development assay (Fig-
ure 3) and inhibiting pericyte association with vessels in
the Fo5 tumor model (Figure S8). We discuss these results
in greater detail below.
NRP1 Is Required for Vascular Remodeling:
A Potential Mechanism for Anti-NRP1
and Anti-VEGF Additive Effects
By systemic delivery of mAbs in neonatal mice, and anal-
ysis of retinal vascular development, we were able to in-
vestigate the role of NRP1 in vascular remodeling. Based
on the Nrp1 knockout phenotypes (Gu et al., 2003; Kawa-
saki et al., 1999; Takashima et al., 2002), we speculated
that acute block of NRP1 function would result in the inhi-
bition of vascular plexus remodeling. Although the exten-
sion of the developing vascular furrow was only slightly
inhibited by treatment with either anti-NRP1 mAb, we
observed a striking inhibition of vascular remodeling.
These results are in contrast to the vessel architecture
observed for anti-VEGF-treated animals, which resulted in
a decrease in vascular complexity and density (Figure 3).
It has been proposed that vascular remodeling in the
retina takes place in the absence of close pericyte associ-
ations, suggesting that pericytes serve to stabilize im-
mature blood vessels ending the plasticity period of vessel
remodeling (Benjamin et al., 1998). Our data suggest that
NRP1 is required for this intricate process of vessel re-
modeling, consisting of themorphogenesis of the vascular
plexus into fine capillaries, followed by further maturation.
Unfortunately, we were unable to evaluate close pericyte
associations in the capillary plexus region in these young
animals, as pericytes are present but not uniformly orga-
nized into capillary beds until later time points in develop-
ment. However, further analysis of retinas treated with
either anti-NRP1 mAb or anti-VEGF showed that arterial
and venous differentiation was not significantly altered
(data not shown). Specifically, mAb treatment did not alter
a-smooth muscle actin distribution on larger vessels at P5
or P8, suggesting that well-established vessels are not
altered by anti-NRP1 or anti-VEGF treatment.
The idea of pericytes stabilizing tumor vessels, thus giv-
ing rise to anti-VEGF therapy resistance as a consequence
of vessels losing their VEGF dependence, has been pro-
posed and tested experimentally (Bergers et al., 2003;
Erber et al., 2004). In these studies, it was observed that
blocking both the function of VEGF (EC ligand) and PDGF
(pericyte ligand) results in further disruption of tumor vas-
culature. Subsequently, it has been shown in elegant im-
aging studies that blocking VEGF function alone in tumors
results in a significant amount of vascular regression;
however, remaining vessels become ‘‘normalized’’ with
close pericyte associations, possibly a consequence of
immature vessels undergoing vascular remodeling and
maturation (Inai et al., 2004).
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hypothesized that blocking NRP1 function in tumors
would also reduce vascular remodeling of tumor vessels
in the presence of anti-VEGF, subsequently inhibiting
vessel maturation, therefore keeping vessels in a state of
VEGF dependence (model shown in Figure 7A). Inhibiting
vessel remodeling alone may not have a significant effect
on reducing tumor growth, as most tumor vessels are
already inherently disorganized (Baluk et al., 2005). This
prediction is consistent with the observation that,
although anti-NRP1A strongly inhibits vascular remodel-
ing, we do not see a single-agent effect with this antibody
in reducing tumor growth. However, we speculated that
blocking vascular remodeling, and the subsequent matu-
ration, in combination with anti-VEGF therapy may render
the remaining tumor vessels more susceptible to regres-
sion. Our experiments showed that vessels remaining
in tumors treated with anti-NRP1 mAbs in combination
with anti-VEGF indeed lack pericyte association (Figure 6
and Figure S8). These results suggest that the additive
effect we observe in blocking both NRP1 and VEGF func-
tion may arise as a consequence of rendering remaining
vessels more vulnerable to regression induced by anti-
VEGF therapy.
Finally, it is possible that NRP1 may also be required for
pericyte function. It has recently been reported that bFGF
induces upregulation of NRP1 on smooth muscle cells, re-
sulting in the ability of VEGF to induce smooth muscle cell
migration (Liu et al., 2005). In our own studies, we ob-
served expression of NRP1 on human smooth muscle
cells, as well as on pericytes in various murine and human
tumors (for example, NRP1 expression extends to areas
adjacent to vessels; Figure 5 and Figure S8). Possible
roles for NRP1 in pericyte function remain to be explored.
NRP1 Expression on Tumor Cells
In addition to the vascular function of NRP1, which is the
focus of this manuscript, others have reported a potential
role for NRP1 expressed on tumor cells (Bielenberg et al.,
2006). In fact, Klagsbrun and colleagues initially cloned
NRP1 as a tumor cell-specific receptor for VEGF (Soker
et al., 1998) and later proposed amodel in which NRP1 re-
ceptors expressed on tumor cells act in trans to enhance
tumor vascularization (Miao et al., 2000). Consistent with
the positive role of NRP1 in tumorigenesis, some reports
documented that the expression of NRP1 in various tumor
types correlates with poor prognosis, advanced disease
state, and invasiveness (Kawakami et al., 2002; Latil
et al., 2000; Vanveldhuizen et al., 2003; Hansel et al.,
2004), and in cell culture, increased expression of NRP1
on tumor cells was found to correlate with survival and
chemoresistance (Bachelder et al., 2001; Wey et al.,
2005). Other reports have, however, suggested that NRP1
is a negative regulator of tumorigenesis in some cases. In
one study, expression of NRP1 in tumor cell lines that nor-
mally do not express NRP1 inhibits the tumorigenic phe-
notype of these cells (Gray et al., 2005). It also has been
recently reported that maintained expression of NRP1 in
colon cancer correlates with a better prognosis (Kamiyaet al., 2006). These studies illustrate the complex function
of NRP1 on tumors.
The tumormodels we selected for this study showmod-
erate to low expression of NRP1 on tumor cells (Figure 5;
Figures S5 and S8). Likewise, we were unable to observe
any effect on SK-MES-1 tumor cell proliferation or induc-
tion of ADCC with our anti-NRP1 mAbs. Nonetheless, we
cannot dismiss the possibility that the additive effect we
observe in reducing tumor growth is in part a consequence
of affecting tumor cell function.
Conclusion
We show that blocking both NRP1 and VEGF function
in tumor models results in an additive effect in reducing
tumor growth. We also present evidence that NRP1 may
also be acting through mechanisms other than VEGFR2
signaling. These data are both unexpected and intriguing
and suggest that blocking NRP1 function may be a useful
approach for enhancing antiangiogenic therapy.
EXPERIMENTAL PROCEDURES
Bead Outgrowth Assay
Dextran-coated Cytodex 3 microcarrier beads (Amersham) were incu-
bated with HUVECs (400 cells per bead) in EGM-2, which contains
2 ng/ml VEGF, overnight at 37C. To induce clotting, 0.5 ml cell-coated
beads in PBS with 2.5 mg/ml fibrinogen (200 beads/ml) was added into
one well of a 24-well tissue culture plate containing 0.625 units throm-
bin and incubated for 5 min at room temperature and then for 20 min
at 37C. The clot was equilibrated in EMG-2 for 30 min at 37C. The
medium was then replaced with EGM-2 containing skin fibroblast cells
(Detroit 551, 20,000 cells/ml). Antibodies were added to each well,
and the assay was monitored for 8 days with change in medium every
2–3 days. Images of the beads were captured by an inverted micro-
scope, and concentric circles spaced at 100, 200, and 300 mm were
drawn around the bead in each image. The number of vessels crossing
each line was counted.
Animal Studies
All studies were conducted in accordance with the Guide for the Care
and Use of Laboratory Animals, published by the NIH (NIH Publication
85-23, revised 1985). An Institutional Animal Care and Use Committee
(IACUC) approved all animal protocols.
Mouse Neonatal Retinal Vascular Assay
Neonatal CD1 mice were injected i.p. with mAbs at 10 mg/kg (5 mg/kg
for combination study). The injections were performed on postnatal
days 1 and 3 for P5 studies, and on days 1, 3, and 5 for P8 studies.
Eyes were collected and fixed with 4% PFA. The dissected retinas
were blocked with 10% mouse serum in PBSt (PBS, 1% Triton
X-100) for 3 hr and then incubated overnight at 4C with 25 mg/ml bio-
tinylated isolectin B4 (Sigma) in PBLEC (1% Triton X-100, 0.1 mM
CaCl2, 0.1 mM MgCl2, 0.1 mM MnCl2, in PBS [pH 6.8]). Retinas were
then washed and stained with Alexa 488 streptavidin (Molecular
Probes). Images of flat-mounted retinas were captured by confocal
fluorescence microscopy.
Tumor Models
For SK-MES-1, each HRLN female nude mouse received a 1 mm3
tumor fragment s.c. implant in the flank. For H1299, 13 107 tumor cells
were injected s.c. into the flank of HRLN female nude mice. Tumor
growth was monitored twice weekly by caliper measurements. When
tumors reached an average size of 80–120 mm3, mice were sorted
to give nearly identical group mean tumor sizes, and treatment was
started. This was considered day 1 of each study. All treatmentsCancer Cell 11, 53–67, January 2007 ª2007 Elsevier Inc. 65
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Anti-NRP1 Antibodies Augment Anti-VEGF Therapywere bodyweight-adjusted at 0.2 ml/20 g. For details on measurement
of %TGI and%TGD, see statistical analysis in the Supplemental Data.
For details on other Experimental Procedures, see the Supplemental
Data.
Supplemental Data
TheSupplementalData includeSupplemental Experimental Procedures
and nine supplemental figures and can be found with this article online
at http://www.cancercell.org/cgi/content/full/11/1/53/DC1/.
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